Market Overview

UPDATE: Stifel Nicolaus Increases PT to $168 on Biogen Idec on Hemophilia Trial

Share:
Related BIIB
Biogen Shares Not Too Healthy After Q1 Miss
Morgan Stanley Reviews Biogen Earnings
Biogen Misses On Tecfidera (Investor's Business Daily)

Stifel Nicolaus reiterated its Buy rating on Biogen Idec (NASDAQ: BIIB) and increased its price target from $167 to $168.

Stifel Nicolaus commented, "Biogen and partner Swedish Orphan Biovitrum (Sobi) announced positive top-line data from the Phase III B-LONG trial of rFIXFc, a long-acting blood clotting factor, in patients with hemophilia B. This condition is currently typically treated with market leader BeneFIX (Pfizer; 2011 WW sales $693M). … We see the B-LONG data as sufficient for rFIXFc approval; we expect a 1H13 filing and mid 2014 launch."

Biogen Idec closed at $151.62 on Wednesday.

Latest Ratings for BIIB

DateFirmActionFromTo
Mar 2015BMO CapitalMaintainsOutperform
Mar 2015CitigroupMaintainsBuy
Mar 2015Stifel NicolausDowngradesBuyHold

View More Analyst Ratings for BIIB
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (BIIB)

Around the Web, We're Loving...